Benzinga's Top #PreMarket Gainers

Omeros OMER soared 10.43% to $9.85 in the pre-market trading after the US FDA granted orphan drug designation to Omeros' OMS721 for complement-mediated thrombotic microangiopathies. BioCryst Pharmaceuticals BCRX surged 7.40% to $6.97 in the pre-market session after the company reported that it has selected two optimized plasma kallikrein inhibitors for hereditary angioedema into preclinical development. Sonus Networks SONS shares jumped 7.26% to $3.25 in pre-market trading. Sonus Networks shares have jumped 66.48% over the past 52 weeks, while the S&P 500 index has gained 24.04% in the same period. Lennar LEN shares gained 3.69% to $36.50 in the pre-market after the company reported a rise in its fiscal fourth-quarter profit.